Neon Therapeutics, Inc. announced upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place March 29 – April 3, 2019 in Atlanta, GA. At the AACR meeting, Neon will be presenting data relating to both its personal neoantigen vaccine, NEO-PV-01, and its personal neoantigen T cell therapy, NEO-PTC-01. Data from the NEO-PV-01 program will include correlative analysis from the melanoma cohort in NT-001, a clinical trial exploring the feasibility, safety, efficacy and immunogenicity of NEO-PV-01 dosed in combination with nivolumab in patients with advanced or metastatic melanoma, non-small cell lung cancer and bladder cancer. Mature clinical outcomes from this study will be presented later in the first half of this year.